Commercial-stage biopharmaceutical company Mirati Therapeutics closed its underwritten public offering at USD 345 million, consisting of 11.3 million common shares at USD 27.80 per share, via an underwritten public offering. The gross proceeds also include pre-funded warrants as an alternative to common stock, allowing investors to purchase up to 1.1 million shares at a per-share exercise price of USD 0.001, lower than the public offering price.
Goldman Sachs & Co. LLC acted as book-running managers, while Leerink Partners LLC acted as financial advisor for the offering.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.